glp-1 uniprot Glucagon-like peptide-1 receptor Personalized GLP-1 Injection
Description
R.PratapU
Tirzepatide demonstrated remarkable weight-reducing efficacy in randomized controlled trials such as SURMOUNT-1 and SURMOUNT-2, with mean body-weight reductions ranging from 15 to 22.5% (32, 33)
He speculates that GLP-1 receptors in some people may have genetic differences that might influence how well the hormone binds to the receptor and activates subsequent insulin and satiety pathways
Kimler Dikkatli Olmal Veya Kullanamamal
